Israel - hebreiska - Ministry of Health

teva pharmaceutical indust.ltd - lercanidipine hydrochloride 10 mg - tablets - lercanidipine - hypertension. mild to moderate essential hypertension.

Israel - hebreiska - Ministry of Health

merck sharp & dohme israel ltd - lisinopril as dihydrate 10 mg - tablets - lisinopril - hypertension: tensopril is indicated for the treatment of essentioal hypertension and renovascular hypertension. tensopril may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. congestive heart failure: tensopril is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. acute myorardial infarction: tensopril is indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction to improve survival.

Israel - hebreiska - Ministry of Health

merck sharp & dohme israel ltd - lisinopril as dihydrate 20 mg - tablets - lisinopril - hypertension: tensopril is indicated for the treatment of essential hypertension and renovascular hypertension. tensopril may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. congestive heart failure: tensopril is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. acute myocardial infarction: tensopril is indicated for the treatment of hemodynamically stable patients within 24 hous of acute myocardial infarction to improve survival.

Israel - hebreiska - Ministry of Health

merck sharp & dohme israel ltd - lisinopril as dehydrate 5 mg - tablets - lisinopril - hypertension: tensopril is indicated for the treatment of essential hypertension and renovascular hypertension.tensopril may be used alone as initial therapy, or concomitantly with other classes of antihypertensive agents. congestive heart failure: tensopril is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. acute myocardial infarction: tensopril is indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction to improve survival.

Israel - hebreiska - Ministry of Health

rafa laboratories ltd - ramipril 2.5 mg - capsules - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.

Israel - hebreiska - Ministry of Health

rafa laboratories ltd - ramipril 5 mg - capsules - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.

Israel - hebreiska - Ministry of Health

rafa laboratories ltd - ramipril 1.25 mg - capsules - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.

Israel - hebreiska - Ministry of Health

teva pharmaceutical indust.ltd - ramipril 2.5 mg - tablets - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

Israel - hebreiska - Ministry of Health

merck sharp & dohme israel ltd - losartan potassium 12.5 mg - tablets - losartan - hypertension: ocsaar is indicated for the treatment of hypertension. heart failure: ocsaar is indicated for the treatment of heart failure (nyha ii) when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to ocsaar is not recommended.

Israel - hebreiska - Ministry of Health

bioavenir ltd - losartan as potassium 50 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin